S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:CTSO

Cytosorbents - CTSO Stock Forecast, Price & News

$1.41
+0.01 (+0.71%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.36
$1.45
50-Day Range
$1.20
$2.03
52-Week Range
$1.18
$5.40
Volume
33,554 shs
Average Volume
122,276 shs
Market Capitalization
$61.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75

Cytosorbents MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
307.8% Upside
$5.75 Price Target
Short Interest
Bearish
1.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Cytosorbents in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$59,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.83) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

713th out of 1,047 stocks

Surgical & Medical Instruments Industry

77th out of 104 stocks

CTSO stock logo

About Cytosorbents (NASDAQ:CTSO) Stock

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

CTSO Stock News Headlines

See More Headlines
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

CTSO Company Calendar

Last Earnings
11/04/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTSO
Employees
221
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.75
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+307.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,560,000.00
Net Margins
-114.61%
Pretax Margin
-116.65%

Debt

Sales & Book Value

Annual Sales
$43.17 million
Book Value
$0.90 per share

Miscellaneous

Free Float
40,581,000
Market Cap
$61.53 million
Optionable
Optionable
Beta
0.62

Key Executives

  • Dr. Phillip P. Chan M.D.Dr. Phillip P. Chan M.D. (Age 52)
    Ph.D., CEO & Director
    Comp: $667.47k
  • Mr. Vincent J. Capponi M.S. (Age 64)
    MS, Pres & COO
    Comp: $539.29k
  • Ms. Kathleen P. Bloch CPAMs. Kathleen P. Bloch CPA (Age 67)
    CPA, M.B.A., MBA, CFO & Sec.
    Comp: $462.11k
  • Dr. Efthymios N. Deliargyris FACC (Age 53)
    FESC, FSCAI, M.D., Chief Medical Officer
    Comp: $521.61k
  • Ms. Terri Anne Powers M.B.A.
    VP of Investor Relations & Corp. Communications
  • Dr. Christian Steiner M.D.
    Exec. VP of Sales & Marketing
  • Mr. Christopher Cramer MBA
    MS, VP of Bus. Devel.
  • Dr. Robert H. Bartlett M.D. (Age 83)
    Co-Chairman of Cardiac Surgery Advisory Board & Consultant













CTSO Stock - Frequently Asked Questions

Should I buy or sell Cytosorbents stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CTSO shares.
View CTSO analyst ratings
or view top-rated stocks.

What is Cytosorbents' stock price forecast for 2023?

1 Wall Street analysts have issued 12 month target prices for Cytosorbents' shares. Their CTSO share price forecasts range from $5.50 to $6.00. On average, they predict the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 307.8% from the stock's current price.
View analysts price targets for CTSO
or view top-rated stocks among Wall Street analysts.

How have CTSO shares performed in 2022?

Cytosorbents' stock was trading at $4.19 on January 1st, 2022. Since then, CTSO shares have decreased by 66.3% and is now trading at $1.41.
View the best growth stocks for 2022 here
.

Are investors shorting Cytosorbents?

Cytosorbents saw a increase in short interest in November. As of November 15th, there was short interest totaling 679,000 shares, an increase of 33.1% from the October 31st total of 510,200 shares. Based on an average trading volume of 167,800 shares, the short-interest ratio is presently 4.0 days. Currently, 1.8% of the company's stock are short sold.
View Cytosorbents' Short Interest
.

When is Cytosorbents' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CTSO earnings forecast
.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical research company earned $9.76 million during the quarter, compared to the consensus estimate of $9.96 million. Cytosorbents had a negative trailing twelve-month return on equity of 80.80% and a negative net margin of 114.61%. During the same period in the previous year, the company earned ($0.02) EPS.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a number of institutional and retail investors. Top institutional investors include Skylands Capital LLC (5.39%), Avenir Corp (5.30%), Neuberger Berman Group LLC (3.39%), Sargent Investment Group LLC (2.54%), CM Management LLC (1.55%) and Renaissance Technologies LLC (0.45%). Insiders that own company stock include Al Kraus, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends
.

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $1.41.

How much money does Cytosorbents make?

Cytosorbents (NASDAQ:CTSO) has a market capitalization of $61.53 million and generates $43.17 million in revenue each year. The medical research company earns $-24,560,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does Cytosorbents have?

The company employs 221 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650.

This page (NASDAQ:CTSO) was last updated on 12/2/2022 by MarketBeat.com Staff